Register for free to
view the full innovation profile.
A simple and efficient method to monitor channel activity for analyzing channels, pumps, and receptors in electrophysiologic studies
About
Introduction: There is an ever-increasing demand for strategies to treat inflammation and auto-immune diseases. In this regard, developing anti-inflammatory agents by targeting positive regulators has been a key strategy. However, this is associated with several adverse effects such as infection susceptibility and induction of apoptosis. To overcome the disadvantages of the current therapeutics, inhibition of negative regulators offers a useful strategy for treating inflammation. Technology: Using this novel approach, Georgia State University researchers have discovered that targeting the tumor suppressor CYLD, a crucial negative regulator of inflammation, is advantageous for treating overactive inflammation in many diseases. The invention discloses methods for treating inflammatory conditions through the upregulation of CYLD, by administering a phosphodiesterase 4 (PDE4) or c-jun-N-terminus kinase 2 (JNK2) inhibitor.
Key Benefits
Could be used for treating upper respiratory infections that cause otitis media, rhinitis, sinusitis and infectious disease-causing inflammation of ear, nose, throat, lung or nasal passage May be a new therapeutic strategy for preventing lung fibrosis Potential treatment of COPD, asthma, bronchitis, pulmonary fibrosis, sarcoidosis and many others Could avoid serious side effects associated with targeting positive regulators of inflammation Could potentially be used for treating infants and children